Literature DB >> 8152238

Determination of 18F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography.

H Miyazawa1, A Osmont, M C Petit-Taboué, I Tillet, J M Travère, A R Young, L Barré, E T MacKenzie, J C Baron.   

Abstract

We have determined the rate constants (ki*) of 18F-fluorodeoxyglucose (FDG) in the unlesioned baboon brain, for use in positron emission tomography (PET) measurements of glucose utilization. In contrast to earlier reports, we used a radiosynthesis which guarantees production of FDG essentially uncontaminated by fluorodeoxymannose, and an improved determination of ki* by (1) direct measurement of the time-shift between bolus arrival in femoral arterial plasma and brain, (2) rapid initial PET frames, and (3) extended data acquisition (up to 180 min). Young adult baboons were studied under anesthesia with either phencyclidine or etomidate. The FDG time-activity curves obtained from temporal grey matter showed a consistent decline after about 80 min, indicating true product loss. Three-compartment modelling was performed for increasing fitting intervals (20-120 min) with both a 5-parameter (K1*-k4*, and vascular volume (Vo)) and a 4-parameter (K1*-k3*,Vo) model. With the latter, both the calculated FDG net clearance ((K* = K1*.k3*/(k2* + k3*)) and the fitted kinetic constants were dependent on fitting interval, i.e., they showed sustained unstability. With the former, the constant k4*, which presumably represents dephosphorylation, was overestimated and unstable for short fitting times (presumably due to heterogeneous brain compartments in the sample tissue), but stabilized at approximately 0.01 min-1 for fitting times > or = 80 min; K1*-k3* and K* were also stable after this time. These findings were identical for both anesthetic regimen. Thus, in the anesthetized baboon, the FDG ki* values can be reliably determined based on an adequate PET acquisition paradigm and with a model that incorporates k4* and > or = 80 min time-activity data.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8152238     DOI: 10.1016/0165-0270(93)90033-n

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  19 in total

1.  Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis.

Authors:  Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Gerlinde Egerer; Julie Vasamiliette; Thomas Schmitt; Uwe Haberkorn; Bernd Kasper
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-25       Impact factor: 9.236

2.  PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.

Authors:  Christos Sachpekidis; Hartmut Goldschmidt; Dirk Hose; Leyun Pan; Caixia Cheng; Klaus Kopka; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

3.  Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study.

Authors:  Christos Sachpekidis; Christian Thieke; Vasileios Askoxylakis; Nils H Nicolay; Peter E Huber; Michael Thomas; Georgia Dimitrakopoulou; Juergen Debus; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

4.  (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.

Authors:  C Sachpekidis; M Eder; K Kopka; W Mier; B A Hadaschik; U Haberkorn; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-12       Impact factor: 9.236

5.  68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer.

Authors:  Christos Sachpekidis; P Bäumer; K Kopka; B A Hadaschik; M Hohenfellner; A Kopp-Schneider; U Haberkorn; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-23       Impact factor: 9.236

6.  Structural and practical identifiability of dual-input kinetic modeling in dynamic PET of liver inflammation.

Authors:  Yang Zuo; Souvik Sarkar; Michael T Corwin; Kristin Olson; Ramsey D Badawi; Guobao Wang
Journal:  Phys Med Biol       Date:  2019-09-05       Impact factor: 3.609

7.  Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Christos Sachpekidis; J Hillengass; H Goldschmidt; B Wagner; U Haberkorn; K Kopka; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-29       Impact factor: 9.236

8.  Evaluation of bone remodeling with (18)F-fluoride and correlation with the glucose metabolism measured by (18)F-FDG in lumbar spine with time in an experimental nude rat model with osteoporosis using dynamic PET-CT.

Authors:  Caixia Cheng; Christian Heiss; Antonia Dimitrakopoulou-Strauss; P Govindarajan; G Schlewitz; Leyun Pan; Reinhard Schnettler; Klaus Weber; Ludwig G Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-03-08

9.  Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.

Authors:  Ludwig G Strauss; Johannes Hoffend; Dirk Koczan; Leyun Pan; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-11       Impact factor: 9.236

10.  Evaluation of new bone formation in normal and osteoporotic rats with a 3-mm femur defect: functional assessment with dynamic PET-CT (dPET-CT) using 2-deoxy-2-[(18)F]fluoro-D-glucose ( (18)F-FDG) and (18)F-fluoride.

Authors:  Caixia Cheng; Volker Alt; Antonia Dimitrakopoulou-Strauss; Leyun Pan; Ulrich Thormann; Reinhard Schnettler; Klaus Weber; Ludwig G Strauss
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.